Pliant Therapeutics Files 8-K: Material Agreements & Bylaw Changes
Ticker: PLRX · Form: 8-K · Filed: Mar 13, 2025 · CIK: 1746473
| Field | Detail |
|---|---|
| Company | Pliant Therapeutics, Inc. (PLRX) |
| Form Type | 8-K |
| Filed Date | Mar 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, corporate-governance, regulatory-filing
TL;DR
Pliant Therapeutics just filed an 8-K detailing a material definitive agreement and changes to its corporate structure.
AI Summary
Pliant Therapeutics, Inc. announced on March 12, 2025, the entry into a material definitive agreement. The company also reported modifications to the rights of its security holders and amendments to its articles of incorporation or bylaws. This filing is a current report under the Securities Exchange Act of 1934.
Why It Matters
This filing indicates significant corporate actions, including new agreements and potential changes to shareholder rights, which could impact the company's strategic direction and investor relations.
Risk Assessment
Risk Level: medium — Material definitive agreements and changes to corporate bylaws can introduce new risks or alter existing ones for the company and its stakeholders.
Key Players & Entities
- PLIANT THERAPEUTICS, INC. (company) — Registrant
- March 12, 2025 (date) — Date of earliest event reported
- 331 Oyster Point Boulevard (address) — Principal Executive Offices
- South San Francisco, CA 94080 (address) — Principal Executive Offices
FAQ
What is the nature of the material definitive agreement entered into by Pliant Therapeutics?
The filing states that Pliant Therapeutics, Inc. entered into a material definitive agreement on March 12, 2025, but the specific details of this agreement are not provided in the excerpt.
What specific modifications were made to the rights of Pliant Therapeutics' security holders?
The filing indicates that there were material modifications to the rights of security holders, but the exact nature of these modifications is not detailed in the provided text.
Are there any amendments to Pliant Therapeutics' articles of incorporation or bylaws mentioned?
Yes, the filing explicitly lists 'Amendments to Articles of Incorporation or Bylaws' as an item of information, suggesting such changes have occurred.
What is the primary business of Pliant Therapeutics, Inc. according to the filing?
Pliant Therapeutics, Inc. is classified under the Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.
When was this 8-K report filed with the SEC?
This 8-K report was filed on March 13, 2025, with the earliest event reported being March 12, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 13, 2025 regarding PLIANT THERAPEUTICS, INC. (PLRX).